Hargreaves R.J.,Biogen |
Hoppin J.,InviCRO LLC |
Sevigny J.,Biogen |
Patel S.,Biogen |
And 3 more authors.
Clinical Pharmacology and Therapeutics
Advances in multimodality fusion imaging technologies promise to accelerate the understanding of the systems biology of disease and help in the development of new therapeutics. The use of molecular imaging biomarkers has been proven to shorten cycle times for central nervous system (CNS) drug development and thereby increase the efficiency and return on investment from research. Imaging biomarkers can be used to help select the molecules, doses, and patients most likely to test therapeutic hypotheses by stopping those that have little chance of success and accelerating those with potential to achieve beneficial clinical outcomes. CNS imaging biomarkers have the potential to drive new medical care practices for patients in the latent phases of progressive neurodegenerative disorders by enabling the detection, preventative treatment, and tracking of disease in a paradigm shift from today's approaches that have to see the overt symptoms of disease before treating it. © © 2015 American Society for Clinical Pharmacology and Therapeutics. Source
Pujatti P.B.,Queen Mary, University of London |
Pujatti P.B.,University of Sao Paulo |
Foster J.M.,Queen Mary, University of London |
Finucane C.,InviCRO LLC |
And 7 more authors.
Applied Radiation and Isotopes
We evaluated and compared a new bombesin analog [Tyr-Gly5, Nle14]-BBN(6-14) conjugated to DOTA or DTPA and radiolabeled with In-111 in low and high GRPR expressing tumor models. Both peptides were radiolabeled with high radiochemical purity and specific activity. In vitro assays on T-47D, LNCaP and PC-3 cells showed that the affinity of peptides is similar and a higher binding and internalization of DOTA-peptide to PC-3 cells was observed. Both peptides could target PC-3 and LNCaP tumors in vivo and both tumor types could be visualized by microSPECT/CT. © 2014 Elsevier Ltd. Source
Invicro Llc | Date: 2011-12-08
A method is provided for estimating a parameter of physiological significance. One or more images are provided of a tissue in a subject to whom a dose of a contrast agent (CA) has been administered, using a computer equipped with image processing software, the concentration or relative concentration of the agent in a region or regions of interest in the tissue is determined, thus generating concentration data. The time-based behavior of concentrations of CA within the tissue is determined using a pharmacokinetic model that is based on a set of pharmacokinetic model parameters. Using computer code, the pharmacokinetic model is fit to the concentration data, varying one or more parameters, such that a best fit estimate of a parameter of physiological significance is provided.
inviCRO LLC | Date: 2010-03-09
Invicro Llc | Date: 2013-06-07
A method of estimating a parameter of physiological significance in the central nervous system (CNS) is provided. The method comprises (a) providing one or more images of the brain or cerebral spinal fluid (CSF) in a subject to whom a dose of a contrast agent (CA) has been administered; (b) determining, using a computer equipped with image processing software, the concentration or relative concentration of the agent in a region or regions of interest in the brain or CSF, thereby generating concentration data; (c) describing the time-based behavior of concentrations of CA within the brain or CSF using a pharmacokinetic model that is based on a set of pharmacokinetic model parameters; and (d) fitting, using computer code, the pharmacokinetic model to the concentration data, varying one or more parameters, wherein the best fit estimates a parameter of physiological significance in the CNS.